(11beta)-11,21-Dihydroxy-3,20-dioxopregn-4-en-17-yl valerate(CAS: 57524-89-7)

This compound falls under the scope of GHS for classification as a chemical substance. Regulatory guidelines include REACH in the European Union, which mandates registration, evaluation, authorization, and restriction of chemicals. In the United States, FDA and EPA regulations may apply based on specific applications and intended uses. Users should consult relevant regulatory bodies for detailed compliance requirements.

For synthesis, several alternatives can be considered, such as using (11beta)-11,21-dihydroxy-3,20-dioxopregn-4-ene-17-one or other steroidal valerate derivatives. These alternatives can offer similar functionalities. It is advisable to evaluate each alternative based on reaction specificity, yield, and cost-efficiency.

Research trends indicate increasing interest in this compound for its potential in biopharmaceutical applications, particularly in hormone therapy and reproductive health. Market trends show growing demand, driven by advancements in drug development and regulatory approvals. Emerging studies focus on its pharmacokinetics and clinical efficacy.

Waste containing this compound should be collected in a sealed container and disposed of according to local waste management regulations. For hazardous waste, professional disposal services should be utilized. Environmental protection measures include proper containment to prevent leaks and ensure safe transport to the disposal site. Users should consult local environmental agencies for specific disposal guidelines.